© 2022 MJH Life Sciences and Oncology Nursing News. All rights reserved.
© 2022 MJH Life Sciences™ and Oncology Nursing News. All rights reserved.
May 15, 2022
Loyda E. Braithwaite, MSN, RN, AGPCNP-BC, AOCNP, highlights nursing considerations in prescribing and administering endocrine therapy to patients with HR+ breast cancer.
May 14, 2022
Entrectinib elicited encouraging responses in patients with breast cancer that harbors NTRK fusions, according to updates from the phase 2 STARTRK-2 trial.
May 09, 2022
Patients with HER2-positive breast cancer who also have brain metastases experienced clinical benefit with fam-trastuzumab deruxtecan-nxki in the phase 2 TUEXEDO-trial.
May 05, 2022
Single nucleotide polymorphism (SNP) genotyping could be used to predict radiation dermatitis in patients with breast cancer.
Fam-trastuzumab deruxtecan-nxki is now an FDA-approved regimen for the treatment of patients with unresectable or metastatic HER2-positive breast cancer.
April 25, 2022
Patients who underwent prospective surveillance with bioimpedance
spectroscopy were less likely to develop chronic breast cancer–related
lymphedema compared with patients who were assessed with tape measure.
April 06, 2022
Sheila Ridner, PhD, RN, FAAN, discusses the implications of the PREVENT study and how oncology nurses can advocate for patients with breast cancer.
April 05, 2022
New data demonstrate that regular exercise can help patients with breast cancer mitigate the physical and mental treatment–related side effects that might impact their quality of life.
March 30, 2022
Hussein A. Tawbi, MD, PhD, principal investigator of the phase 2/3 RELATIVITY-046 trial, highlights the importance of relatlimab/nivolumab’s recent FDA approval in melanoma.
March 28, 2022
Charles E. Geyer, MD, FACP, discusses dosing strategies and adverse event management with olaparib.